Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Oleksandr Voitko"'
Autor:
Marina Chiara Garassino, J.H. Ji, Nikunj Patel, Y. Chen, Jonathan W. Goldman, György Losonczy, Norah J. Shire, Galina Statsenko, Katsuyuki Hotta, Haiyi Jiang, Oleksandr Voitko, Libor Havel, D. Trukhin, Maximilian Hochmair, Peter J. Laud, Mikhail Dvorkin, A. Poltoratskiy, Niels Reinmuth, Luis Paz-Ares, Mustafa Ozguroglu
OZGUROGLU, MUSTAFA/0000-0002-8417-8628 WOS:000579504300008 PubMed ID: 32961445 Objectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf33c41b74bbe8b2dd8b0bf98d18cb3d
https://eprints.whiterose.ac.uk/166497/3/PIIS0169500220306000.pdf
https://eprints.whiterose.ac.uk/166497/3/PIIS0169500220306000.pdf
Autor:
Jonathan W. Goldman, Francesco Verderame, T. Dalvi, D. Trukhin, A. Poltoratskiy, Y. Chen, Oleksandr Voitko, Nikolay Conev, H. Jiang, György Losonczy, Luis Paz-Ares, Mustafa Ozguroglu, I. Bondarenko, Niels Reinmuth, Helen Broadhurst, Katsuyuki Hotta, Galina Statsenko, Libor Havel, J.H. Ji, Maximilian Hochmair
Publikováno v:
Annals of Oncology. 32:S1338
Autor:
A. Franks, Niels Reinmuth, Yashaswi Shrestha, Marina Chiara Garassino, Katsuyuki Hotta, A. Poltoratskiy, D. Trukhin, Galina Statsenko, Igor Bondarenko, Jonathan W. Goldman, Haruhiro Saito, Oleksandr Voitko, Maximilian Hochmair, Stephanie Jones, Y. Chen, Nikolay Conev, Stuart Spencer, Mingchao Xie, J.H. Ji, Luis Paz-Ares, Mustafa Ozguroglu
Publikováno v:
Annals of Oncology. 32:S289
Autor:
Mingchao Xie, Yashaswi Shrestha, Stuart Spencer, M.C. Garassino, Stephanie Jones, A. Franks, Katsuyuki Hotta, Oleksandr Voitko, Luis Paz-Ares, Y. Chen, D. Trukhin, Nikolay Conev, A. Poltoratskiy, Mustafa Ozguroglu, I. Bondarenko, Jonathan W. Goldman, Niels Reinmuth, J.H. Ji, Maximilian Hochmair, Galina Statsenko
Publikováno v:
Annals of Oncology. 31:S1212-S1213
Autor:
Igor Bondarenko, Francesco Verderame, Norah J. Shire, Luis Paz-Ares, Santiago Ponce, Mustafa Ozguroglu, J.H. Ji, A. Poltoratskiy, Libor Havel, Andrzej Kazarnowicz, György Losonczy, Katsuyuki Hotta, Niels Reinmuth, Y. Chen, Nikolay Conev, Maximilian Hochmair, H. Jiang, Jonathan H. Goldman, Jon Armstrong, D. Trukhin, Galina Statsenko, N. Byrne, Oleksandr Voitko
Publikováno v:
Journal of Thoracic Oncology. 14:S7-S8
Autor:
Maximilian Hochmair, Nikunj Patel, M. Dvorkin, Libor Havel, Katsuyuki Hotta, M.C. Garassino, J.H. Ji, Jonathan W. Goldman, H. Jiang, A. Poltoratskiy, Y. Chen, Helen Mann, D. Trukhin, Yashaswi Shrestha, Niels Reinmuth, György Losonczy, Luis Paz-Ares, Mustafa Ozguroglu, Galina Statsenko, Oleksandr Voitko
Publikováno v:
Publons
Background In the phase III CASPIAN trial, durvalumab (D) in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved the primary endpoint of OS vs EP alone in pts with extensive-stage small-cell lung cancer (ES-SCL
Autor:
Francesco Verderame, Galina Statsenko, Libor Havel, Jonathan W. Goldman, Y. Chen, György Losonczy, A. Lloyd, Y. Zheng, A. Poltoratskiy, D. Trukhin, Haiyi Jiang, J.H. Ji, M. Dvorkin, Niels Reinmuth, Katsuyuki Hotta, Maximilian Hochmair, M. Thomas, Luis Paz-Ares, Mustafa Ozguroglu, Oleksandr Voitko
Publikováno v:
Annals of Oncology. 30:xi66
Background CASPIAN is a phase 3, open-label study of 1L platinum-etoposide (EP) ± durvalumab (D) ± tremelimumab (T) for pts with ES-SCLC. D+EP significantly improved OS vs EP alone (HR 0.73 [95% CI 0.59–0.91]; p = 0.0047) at a planned interim ana